GLP-1 Drugs Tied to Mortality Reduction in Colon Cancer Patients With Obesity
(MedPage Today) — SAN FRANCISCO — Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and fewer serious non-cancer complications, a propensity-matched cohort study showed. The retrospective…
该机构预计，到2030年，口服药物将占据GLP-1减肥药市场25%至50%的份额。
Structure expects pills to capture 25% to 50% of GLP-1 obesity market by 2030 (www.reuters.com) 04:00
I’m an RD—Here Are 4 Steps I Recommend Before Starting a GLP-1
These will help you build a supportive foundation for the body.
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. It’s Day 3 of JPM and all of us — Matt, Elaine, Adam, and Allison — are still here! Also, surprisingly, it’s not raining here in San Francisco, as it usually is around JPM. (Remember the umbrellas?) The Readout Loud […]
FDA asks that suicide warning labels be taken off GLP-1 weight-loss drugs
The Food and Drug Administration said Tuesday that it wants suicide warning labels on GLP-1 weight-loss drugs to be removed.
Mission Foods: NEW YEAR, NEW NUTRITION PLAN!
From GLP-1 to Keto, hear the nutrition tips and recipes you need to stay on track in the New Year IRVING, Texas, Jan. 14, 2026 /PRNewswire/ — BACKGROUND: As the calendar turns from December to January, millions of Americans vow that this will be the year they stick to their New Year’s…
Compounding pharmacy sues Lilly, Novo over GLP-1 drug competition
Post Content
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
But the labels — unlike the popular medications themselves — aren’t regulated by the FDA.
Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety
by Ariana M. Chao, Adam Gilden, Thomas A. Wadden Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care. In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden […]
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value in recent years. It has a leading GLP-1 drug that’s approved for diabetes (Mounjaro) and weight loss (Zepbound). Those products are generating billions in revenue for the business every quarter. What’s encouraging, however, […]